Sandbox:Asra: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
[[User:Asra|Asra Firdous,M.B.B.S.]][mailto:asra.firdous21@gmail.com]
[[User:Asra|Asra Firdous,M.B.B.S.]][mailto:asra.firdous21@gmail.com]
__NOTOC__
{{Ewing's sarcoma}}
{{CMG}};{{AE}} {{PSK}};'''Assistant Editor(s)-In-Chief:''' [[User:Michael Maddaleni|Michael Maddaleni, B.S.]], [[User:Asra|Asra Firdous, M.B.B.S.]]
==Overview==
[[Ewing's sarcoma]] is the second most common [[malignant bone neoplasm]] commonly affecting children and adolescents. It usually affects patients in the second decade of life with a peak incidence around 15 years of age. It comprises 3% of all [[malignancies]] in pediatric patients and about 10-15% of [[childhood bone cancers]]. The overall incidence of [[Ewing's sarcoma]] is approximately estimated at 2.9 cases per million population in the U.S. [[Ewing's sarcoma]] is more common in males than females. It is more prevalent in whites than Africans.
==Epidemiology and Demographics==
*[[Ewing's Sarcoma]] is the second most common [[bone malignancy]] in children and adolescents.
*10-15% of childhood bone cancers are [[Ewing's Sarcoma]].
*[[Ewing's Sarcoma]] constitutes about 4% of [[pediatric cancers]].
*200-250 new cases of [[Ewing's sarcoma]] are reported each year in the United States.
*Nearly, 60% of the [[Ewing Sarcoma]] cases have long-term disease-free survival.
===Incidence===
*The [[incidence]] of [[Ewing's sarcoma]] has remained unchanged for 30 years.<ref name=NIH>Ewing's sarcoma. National cancer institute.http://www.cancer.gov/types/bone/hp/ewing-treatment-pdq#section/_1</ref>
*In the United States, the overall [[incidence]] of [[Ewing's sarcoma]] is 1 cases per million individuals.
* During 1973-2004, the average annual [[incidence]] of [[Ewing's Sarcoma]] was estimated to be 2.9 cases per million population in the United States.
*The [[incidence]] of [[Ewing's Sarcoma]], in the United States, is estimated to be 200-250 cases annually.
===Mortality/Morbidity===
The overall 5-year survival rate for patients with [[Ewing's Sarcoma]] is approximately 70% in primary lesions and 30% in [[metastatic]] disease.
===Race===
*[[Ewing's Sarcoma]] is more prevalent in Caucasians than Asians or Hispanics.
*African Americans and Africans are less likely to develop [[Ewing's Sarcoma]].
*The incidence in the Caucasians is 1.5 cases per million population.
*The incidence in the Asians is 0.8 cases per million population.
*The incidence in Africans is 0.2 cases per million population.
===Age===
*[[Ewing's Sarcoma]] commonly affects children and adolescents between 10 and 20 years of age.
*The median age at diagnosis is 15 years
*In patients younger than 5 years, diagnosed in about 0.6 cases per million population.
*In patients aged 10-14 years, diagnosed in about more than 5 cases per million population.
===Gender===
*Males are more commonly affected than females. The male to female ratio is around 3:2.
===Reference===

Revision as of 16:44, 13 June 2020

Asra Firdous,M.B.B.S.[1]


Ewing's sarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Ewing's sarcoma from other diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Biopsy

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sandbox:Asra On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sandbox:Asra

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sandbox:Asra

CDC on Sandbox:Asra

Sandbox:Asra in the news

Blogs on Sandbox:Asra

Directions to Hospitals Treating Ewing's sarcoma

Risk calculators and risk factors for Sandbox:Asra

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2];Associate Editor(s)-in-Chief: Suveenkrishna Pothuru, M.B,B.S. [3];Assistant Editor(s)-In-Chief: Michael Maddaleni, B.S., Asra Firdous, M.B.B.S.

Overview

Ewing's sarcoma is the second most common malignant bone neoplasm commonly affecting children and adolescents. It usually affects patients in the second decade of life with a peak incidence around 15 years of age. It comprises 3% of all malignancies in pediatric patients and about 10-15% of childhood bone cancers. The overall incidence of Ewing's sarcoma is approximately estimated at 2.9 cases per million population in the U.S. Ewing's sarcoma is more common in males than females. It is more prevalent in whites than Africans.

Epidemiology and Demographics

Incidence

Mortality/Morbidity

The overall 5-year survival rate for patients with Ewing's Sarcoma is approximately 70% in primary lesions and 30% in metastatic disease.

Race

  • Ewing's Sarcoma is more prevalent in Caucasians than Asians or Hispanics.
  • African Americans and Africans are less likely to develop Ewing's Sarcoma.
  • The incidence in the Caucasians is 1.5 cases per million population.
  • The incidence in the Asians is 0.8 cases per million population.
  • The incidence in Africans is 0.2 cases per million population.

Age

  • Ewing's Sarcoma commonly affects children and adolescents between 10 and 20 years of age.
  • The median age at diagnosis is 15 years
  • In patients younger than 5 years, diagnosed in about 0.6 cases per million population.
  • In patients aged 10-14 years, diagnosed in about more than 5 cases per million population.

Gender

  • Males are more commonly affected than females. The male to female ratio is around 3:2.

Reference

  1. Ewing's sarcoma. National cancer institute.http://www.cancer.gov/types/bone/hp/ewing-treatment-pdq#section/_1